Oncology Practices May Be Hurt by Medicare Drug Price Negotiations

The U.S. Department of Health and Human Services (HHS) is set to negotiate with drug manufacturers over the maximum prices that Medicare will pay for certain treatments. Those new prices will become effective starting in 2026. A new commentary published today in JAMA Oncology argues that these negotiations, combined with the current Medicare reimbursement model, could have dire consequences for the financial health of community oncology practices.